Circio announces publication of two abstracts selected for presentation at the ASGCT annual meeting

27 Apr 2026 22:30 CEST

* Circio has been selected for a poster presentation on 13 May and an oral
presentation on 15 May at the 2026 ASGCT annual meeting in Boston
* ASGCT is the most important and prestigious gene and cell therapy conference
globally
* The abstracts have been released to the market today, 27 April 2026

Oslo, Norway, 27 April 2026 -- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA expression technology for gene and cell
therapy, today announces the publication of two circVec AAV gene therapy
abstracts accepted to the American Society of Gene and Cell Therapy annual
meeting in Boston 11-15 May 2026. One abstract has been selected for oral
presentation, and the other for poster presentation.

The two abstracts to be presented by Circio both relate to the application of
its circular RNA-based gene expression technology, circVec, to enhance the
performance of AAV gene therapy. The oral presentation will describe the
overall circVec platform and highlight its strong performance and versatility
across multiple tissues in vivo. The poster presentation will focus more
specifically on circVec gene therapy applications in the heart. This
presentation summarizes a robust and reproducible data package showing 40-fold
enhanced gene expression and the underlying mechanism of action effectuating
its substantial increase in performance vs. conventional mRNA-based AAVs.

"ASGCT is the most important event of the year in the gene therapy field, and
Circio is very honored that the scientific committee has selected one of our
abstracts for an oral presentation," said Dr. Thomas B Hansen, CTO of Circio.
"Circio s in vivo data clearly demonstrates that the circVec technology has
the potential to transform conventional AAV gene therapy. The ASGCT
presentation will be an important opportunity to showcase the performance and
versatility of our circVec platform for gene and cell therapy applications to
prospective pharma partners and a wider life science industry and academic
audience."

The ASGCT annual meeting is the largest and most prestigious gene and cell
therapy conference globally, and widely attended by pharmaceutical and biotech
professionals, academics and life science media. Only a small number of
submitted abstracts are accepted for oral presentation.

Circio R&D management will present the two attached abstracts at ASGCT 2026:

Circular RNA-based AAV gene therapy for cardiomyopathies enhances transgene
expression levels, reduces liver off-targeting and minimizes cellular stress
O Leary et al., poster presentation, Wednesday 13 May 2026

circVec: A powerful circular RNA expression platform that enhances AAV
transgene output and enables significant dose reduction O Leary et al.,
oral presentation, Friday 15 May 2026 at 16:15 EST

The materials will be made available on the Circio website shortly after the
ASGCT presentations.

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 50-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

More information:
Access the news on Oslo Bors NewsWeb site

671571_ASGCT2026 Circio 2.pdf
671571_ASGCT2026 Circio 1.pdf